Výsledky vyhledávání - Robert T. Heelan

Upřesnit hledání
  1. 1
    Detection of true pathologic stage I lung cancer in a screening program and the effect on survival

    Detection of true pathologic stage I lung cancer in a screening program and the effect on survival Autor Myron R. Melamed, Betty J. Flehinger, Muhammad Zaman, Robert T. Heelan, Ellen T. Hallerman, Nael Martini

    Vydáno 1981
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Overdiagnosis in chest radiographic screening for lung carcinoma

    Overdiagnosis in chest radiographic screening for lung carcinoma Autor David F. Yankelevitz, William J. Kostis, Claudia I. Henschke, Robert T. Heelan, Daniel M. Libby, Mark Pasmantier, James P. Smith

    Vydáno 2003
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Comparative merits of conventional, computed tomographic, and magnetic resonance imaging in assessing mediastinal involvement in surgically confirmed lung carcinoma

    Comparative merits of conventional, computed tomographic, and magnetic resonance imaging in assessing mediastinal involvement in surgically confirmed lung carcinoma Autor Nael Martini, Robert T. Heelan, Jack Westcott, Manjit S. Bains, Patricia McCormack, James F. Caravelli, Robin C. Watson, Muhammad Zaman

    Vydáno 1985
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Prospective evaluation of unilateral adrenal masses in patients with operable non-small-cell lung cancer

    Prospective evaluation of unilateral adrenal masses in patients with operable non-small-cell lung cancer Autor Michael Burt, Robert T. Heelan, Daniel G. Coit, Patricia McCormack, Manjit S. Bains, Nael Martini, Valerie W. Rusch, Robert J. Ginsberg

    Vydáno 1994
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial

    Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial Autor Raja M. Flores, Lee M. Krug, Kenneth E. Rosenzweig, Ennapadam Venkatraman, A. Vincent, Robert T. Heelan, Tim Akhurst, Valerie W. Rusch

    Vydáno 2006
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Influence of Type of Cigarette on Peripheral versus Central Lung Cancer

    Influence of Type of Cigarette on Peripheral versus Central Lung Cancer Autor Daniel R. Brooks, John H. M. Austin, Robert T. Heelan, Michelle S. Ginsberg, Victor Shin, Sara H. Olson, Joshua Muscat, Steven D. Stellman

    Vydáno 2005
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Predictors of survival in malignant tumors of the sternum

    Predictors of survival in malignant tumors of the sternum Autor Nael Martini, Andrew G. Huvos, Michael Burt, Robert T. Heelan, Manjit S. Bains, Patricia McCormack, Valerie W. Rusch, Michael Weber, Robert J. Downey, Robert J. Ginsberg

    Vydáno 1996
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer

    Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer Autor Vincent A. Miller, James R. Rigas, Prudence A. Francis, Stefan C. Grant, Katherine M.W. Pisters, Mark G. Kris, Karen Woolley, Ennapadam Venkatraman, Robert T. Heelan

    Vydáno 1995
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

    KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Autor William Pao, Theresa Y. Wang, Gregory J. Riely, Vincent A. Miller, Qiulu Pan, Marc Ladanyi, Maureen F. Zakowski, Robert T. Heelan, Mark G. Kris, Harold Varmus

    Vydáno 2005
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancer

    A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancer Autor Daniel T. Milton, Christopher G. Azzoli, Robert T. Heelan, Ennapadam Venkatraman, Jorge Gómez, Mark G. Kris, Lee M. Krug, William Pao, Naiyer A. Rizvi, Megan Dunne, Vincent A. Miller

    Vydáno 2006
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Practical Management of Patients With Non–Small-Cell Lung Cancer Treated With Gefitinib

    Practical Management of Patients With Non–Small-Cell Lung Cancer Treated With Gefitinib Autor Neelam Shah, Mark G. Kris, William Pao, Leslie B. Tyson, Barbara M. Pizzo, Murk‐Hein Heinemann, Leah Ben‐Porat, Dana L. Sachs, Robert T. Heelan, Vincent A. Miller

    Vydáno 2004
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancer

    Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancer Autor Daniel T. Milton, Gregory J. Riely, Christopher G. Azzoli, Jorge Gómez, Robert T. Heelan, Mark G. Kris, Lee M. Krug, William Pao, Barbara Pizzo, Naiyer A. Rizvi, Vincent A. Miller

    Vydáno 2007
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non–Small-Cell Lung Cancer

    Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non–Small-Cell Lung Cancer Autor Naiyer A. Rizvi, Gregory J. Riely, Christopher G. Azzoli, Vincent A. Miller, Kenneth Ng, John J. Fiore, Gloria Chia, Martin Brower, Robert T. Heelan, Michael Hawkins, Mark G. Kris

    Vydáno 2008
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    Imatinib mesylate lacks activity in small cell lung carcinoma expressing c‐kit protein

    Imatinib mesylate lacks activity in small cell lung carcinoma expressing c‐kit protein Autor Lee M. Krug, John P. Crapanzano, Christopher G. Azzoli, Vincent A. Miller, Naiyer A. Rizvi, Jorge Gómez, Mark G. Kris, Barbara Pizzo, Leslie B. Tyson, Megan Dunne, Robert T. Heelan

    Vydáno 2005
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer

    Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer Autor Katharine A. Price, Christopher G. Azzoli, Lee M. Krug, M. Catherine Pietanza, Naiyer A. Rizvi, William Pao, Mark G. Kris, Gregory J. Riely, Robert T. Heelan, Maria E. Arcila, Vincent A. Miller

    Vydáno 2010
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  16. 16
    Preoperative chemotherapy for stage IIIa (N2) lung cancer: The Sloan-Kettering experience with 136 patients

    Preoperative chemotherapy for stage IIIa (N2) lung cancer: The Sloan-Kettering experience with 136 patients Autor Nael Martini, Mark G. Kris, Betty J. Flehinger, Richard J. Gralla, Manjit S. Bains, Michael Burt, Robert T. Heelan, Patricia McCormack, Katherine M.W. Pisters, James R. Rigas, Valerie W. Rusch, Robert J. Ginsberg

    Vydáno 1993
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  17. 17
    Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma

    Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma Autor Lee M. Krug, Vincent A. Miller, Jyoti D. Patel, John P. Crapanzano, Christopher G. Azzoli, Jorge Gómez, Mark G. Kris, Robert T. Heelan, Barbara Pizzo, Leslie B. Tyson, Christine E. Sheehan, Jeffrey S. Ross, Ennapadam Venkatraman

    Vydáno 2005
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non–small cell lung cancer

    Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non–small cell lung cancer Autor Carolyn E. Reed, David H. Harpole, Katherine E. Posther, Sandra Woolson, Robert J. Downey, Bryan F. Meyers, Robert T. Heelan, Homer A. Macapinlac, Sin‐Ho Jung, Gerard A. Silvestri, Barry A. Siegel, Valerie W. Rusch

    Vydáno 2003
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  19. 19
    EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

    EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib Autor William Pao, Vincent A. Miller, Maureen F. Zakowski, Jennifer A. Doherty, Katerina Politi, Inderpal S. Sarkaria, Bhuvanesh Singh, Robert T. Heelan, Valerie W. Rusch, Lucinda A. Fulton, Elaine R. Mardis, Doris M. Kupfer, Richard K. Wilson, Mark G. Kris, Harold Varmus

    Vydáno 2004
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  20. 20
    Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the <i>EGFR</i> Gene

    Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutatio... Autor Naiyer A. Rizvi, Valerie W. Rusch, William Pao, Jamie E. Chaft, Marc Ladanyi, Vincent A. Miller, Lee M. Krug, Christopher G. Azzoli, Manjit S. Bains, Robert J. Downey, Raja M. Flores, Bernard J. Park, Bhuvanesh Singh, Maureen F. Zakowski, Robert T. Heelan, Ronglai Shen, Mark G. Kris

    Vydáno 2011
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: